Related Experiment Video
Updated: Apr 30, 2026

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
Acute exposure to fine ambient particulate matter and pulmonary exacerbations in cystic fibrosis: A case-crossover
Stephen P Colegate1,2, Erika Rasnick Manning2, Andrew Vancil2
1Department of Pediatrics, Cincinnati Children's Hospital Medical Center, United States.
Abstract:
In cystic fibrosis (CF) lung disease, increased exposure to PM2.5 (particulate matter <2.5 μm in diameter) has been linked to more frequent pulmonary exacerbations, yet the timing of exposure that presents the greatest exacerbation risk remains uncertain. Our study investigated whether short-term increases in ambient fine particulate matter (PM2.5) contribute to exacerbation risk in individuals with CF. We analyzed data from 108 participants across 17 U.S. clinical sites enrolled in the Early Intervention in Cystic Fibrosis Exacerbation study (October 2011-July 2015), who recorded forced expiratory volume in 1 s (FEV1) measurements at least twice weekly. Exacerbation cases were identified via the FEV1 indicated exacerbation signal (FIES), defined as a ≥10 % predicted decline in FEV1. Daily 24-h average PM2.5 concentrations were estimated at the residential ZIP code using a high-resolution spatiotemporal exposure model. A time-stratified case-crossover design modeled exacerbation onset and PM2.5 exposure, controlled for temperature, relative humidity, and holiday impacts. We analyzed 6936 FEV1 observations yielding 1432 exacerbation cases, averaging 7.7 cases per person-year, matched to 4794 control dates in the same year, month, and day of the week. Increased exacerbation risk occurred one (OR: 1.18; 95 % CI: 1.02-1.36), two (OR: 1.20; 95 % CI: 1.04-1.40), and three (OR: 1.23; 95 % CI: 1.05-1.43) days after PM2.5 exposure, but not on the day of onset (OR: 1.07; 95 % CI: 0.92-1.25). Integrating home-monitored lung function with hyperlocal exposure estimates provides improved temporal resolution for detecting acute environmental triggers and may inform early intervention strategies in CF care. e-ICE clinical trial registered with clinicaltrials.gov/ (NCT01104402).
Related Concept Videos
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease I: Introduction
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Obstructive Pulmonary Disease II: Emphysema
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Cystic Fibrosis: Management
Sinus disease and chronic...

